Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah’s Witness Patient With Ph-Negative B-ALL

Sarina Koilpillai; Rida Altaf; Alejandro El Barche Palmera; Hatem Hassanein; Stephen J. Carlan

doi:10.12659/AJCR.950606

31 January 2026 : Case report USA

Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah’s Witness Patient With Ph-Negative B-ALL

Unusual clinical course, Clinical situation which can not be reproduced for ethical reasons

Sarina Koilpillai^{ABCDEF 1}, Rida Altaf^{BDEF 2}, Alejandro El Barche Palmera^{ADE 1}, Hatem Hassanein^{BCE 3}, Stephen J. Carlan

^{BCEF 4*}

DOI: 10.12659/AJCR.950606

Am J Case Rep 2026; 27:e950606

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 ClonoSEQ from bone marrow aspirate revealing 0 residual clonal cells after 2 cycles of inotuzumab. IGH – immunoglobulin heavy chain; MRD – minimal residual disease.

Back to the Article

Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah’s Witness Patient With Ph-Negative B-ALL

Your Privacy